SCHEMBL20074103

SCHEMBL20074103

CC(C)(C)c1c(-c2ccc(F)cc2)[nH]c2ncnn2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 2/20 0.42
EGLN2 Q96KS0 1/20 0.36
MAPK14 Q16539 3/20 0.35
BRAF P15056 1/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34
BRD4 O60885 1/20 0.34
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
LMNA P02545 2/20 0.33
PKM P14618 1/20 0.33
GCGR P47871 1/20 0.33
TSHR P16473 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
CYP2C19 P33261 1/20 0.31
RECQL P46063 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20074328 0.80 KDM5B (0.44) KDM5BEGLN2MAPK14BRD4PTGS1
SCHEMBL20074104 0.79 KDM5B (0.45) KDM5BBRD4TSHR
SCHEMBL20074102 0.78 KDM5B (0.46) KDM5BBRD4TSHR
SCHEMBL21721676 0.76 KDM5B (0.50) KDM5BALDH1A1BRD4LMNATSHR
SCHEMBL20074269 0.74 PTGS1 (0.47) KDM5BEGLN2MAPK14PTGS1PTGS2
SCHEMBL20074300 0.74 TSHR (0.36) MAPK14ALDH1A1TSHRMEN1KMT2A
SCHEMBL20074186 0.69 KIT (0.41) EGLN2KDM4EALDH1A1LMNAPKM
SCHEMBL21681723 0.69 KDM5B (0.53) KDM5BKDM4EALDH1A1LMNATSHR
SCHEMBL21681718 0.67 KDM5B (0.54) KDM5BALDH1A1LMNATSHRNPC1
SCHEMBL20074233 0.67 KDM5B (0.52) KDM5BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP claimed
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP disclosed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US disclosed
US-20200048258-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 US disclosed
WO-2018071283-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048258-A1 KDM5 INHIBITORS KDM5A, KDM5B, KDM5C KDM5B 2/4885EGLN2 600/4885MAPK14 1079/4885
US-10975084-B2 KDM5 inhibitors KDM5A, KDM5B, KDM5C KDM5B 2/4885EGLN2 600/4885MAPK14 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.